로딩 중…
지수 로딩 중…
AptaBio Therapeutics Inc.
293780· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,500-4.36%
2026-06-19
Price Chart
AptaBio Therapeutics Inc.-43.68%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 126.42B KRW |
| Revenue | 4.27B KRW |
| Net Income | -20.21B KRW |
| Total Assets | 53.75B KRW |
| Net Assets | 40.89B KRW |
| Employees | 34 |
| Value | |
| P/B | 3.09x |
| P/S | 29.59x |
| Profitability | |
| ROE | -49.42% |
| ROA | -37.60% |
| Op. Margin | -451.87% |
| Revenue Growth | 150.17% |
| Financial Health | |
| Debt Ratio | 131.43% |
| Total Debt | 12.28B KRW |
| Cash | 7.82B KRW |
| Current Ratio | 1.72x |
| Performance | |
| 1Y Return | -43.68% |
| 1M Return | -28.57% |
| From 52W High | -62.37% |
| 1Y MDD | -56.90% |
| Trading | |
| Volume | 152,701 shares |
| Foreign Own. | 2.75% |
| Per Share | |
| EPS | -743 KRW |
| BPS | 1,456 KRW |
Company Info
Aptabio, established in 2009 and specially listed on KOSDAQ in 2019, is a new drug development company based on platform technology, headquartered in Yongin-si, Gyeonggi-do. The company develops innovative new drugs, including for diabetes complications and as immune-oncology agents, utilizing three platform technologies: oxidative stress regulation, CAF modulation, and aptamer-drug conjugates. Aptabio launched health functional food Original Design Manufacturer (ODM) and pet care businesses in 2023, plans to merge Objectivo in 2025, and has successfully achieved three technology transfers with its proprietary technologies.